scispace - formally typeset
V

Vimala N. Bharadwaj

Researcher at Arizona State University

Publications -  14
Citations -  249

Vimala N. Bharadwaj is an academic researcher from Arizona State University. The author has contributed to research in topics: Traumatic brain injury & Medicine. The author has an hindex of 4, co-authored 11 publications receiving 147 citations. Previous affiliations of Vimala N. Bharadwaj include Stanford University & University of Arizona.

Papers
More filters
Journal ArticleDOI

Nanoparticle-Based Therapeutics for Brain Injury.

TL;DR: The focus of this progress report is to provide a survey of NP strategies employed in cerebral ischemia and brain trauma and provide insights for improved NP‐based diagnostic/treatment approaches.
Journal ArticleDOI

Temporal assessment of nanoparticle accumulation after experimental brain injury: Effect of particle size.

TL;DR: The accumulation of particles up to 500 nm at different times acutely after injury is characterized, indicating the potential of NP-based TBI theranostics in the acute period after injury.
Journal ArticleDOI

Blood-brainbarrier disruption dictates nanoparticle accumulation following experimental brain injury.

TL;DR: This study provides the groundwork for feasibility of NP-delivery based on NPinjection time and NPsize after mCHI/RmCHI and midline-FPI and shows that midlineFPI resulted in significant peak accumulation of up to 500 nm NP at 3 h post-injury compared to sham, 1 h, and 6 h groups in the cortex.
Journal ArticleDOI

Sex-Dependent Macromolecule and Nanoparticle Delivery in Experimental Brain Injury

TL;DR: A sex-dependent temporal profile of blood/brain barrier disruption in a preclinical mouse model of traumatic brain injury (TBI) that contributes to starkly different macromolecule and nanoparticle delivery profiles post-TBI is identified.
Journal ArticleDOI

Intranasal Administration for Pain: Oxytocin and Other Polypeptides

TL;DR: In this paper, the authors discuss the delivery of polypeptides to the peripheral and central nervous systems following intranasal (IN) administration and briefly discuss the mechanism of delivery via the nasal-cerebral pathway.